コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 tended to have a thicker choroid than females; however, the difference was not significant.
2 d 20/200 or better vision 5 years after treatment, but this difference was not significant.
3 s for these transcripts in retinas of KO mice, although the difference was not significant.
4 justed odds ratio [aOR], 1.79; 95% CI, 0.99-3.21), but this difference was not significant.
5 e symptom onset compared with those given placebo, but this difference was not significant.
6 % and 69.0% of the CMA patients, respectively, however, the difference was not significant.
7 A were higher in conventional than in organic flours, this difference was not significant.
8 treatment than did those given placebo, but by week 2 this difference was not significant.
9 alateral foot-slips on the tapered balance beam, though the difference was not significant.
10 of highly myopic patients versus 2.1% of controls, but the difference was not significant.
11 ratio [OR] 1.73 [95% CI 0.93-3.22], p=0.085), although this difference was not significant.
12 d by major protocol deviations in 8.5% of the patients, the difference was not significant.
13 ere similar to those of all bloodstream infections, but the difference was not significant.
14 When PEF was combined with US at low temperatures the difference was not significant.
15 al rectus (81% to 49%; P = .11; 95% CI, -2.06 to 0.22), the difference was not significant.
17 were pound513 versus pound561 in the control group but this difference was not significant (95% CI- pound353 to pound257,
18 Equivalence in total 2-year costs was not achieved, but the difference was not significant (adjusted mean difference poun
19 % in inner-city and 10.6% in non-inner-city areas, but this difference was not significant after adjusting for race/ethni
21 oup; however, when periprocedural events were excluded, the difference was not significant; and (4) a significant reducti
22 e baseline level at 6 months (40% vs. 24%, P=0.01), but the difference was not significant at 12 months (31% vs. 20%, P=0
23 e points (95% CI, 3.7 to 33.3; P=0.01); the unadjusted risk difference was not significant at the 24-month secondary outc
24 ery (p=0.045) than did those in the placebo group, but this difference was not significant at week 5.
25 y a two-sided Fisher's exact test in the NIH trial) but the difference was not significant at week 8.
26 tion in vomiting frequency compared with baseline, but this difference was not significant compared with the placebo grou
27 5% CI 1.02-1.56) than were those with HIV only, whereas the difference was not significant for those with HBV co-infectio
29 plus prednisone (19.4 months [16.6-not estimable]), but the difference was not significant (HR 0.85, 95% CI 0.69-1.04; p=
30 us placebo in patients with previous docetaxel use, but the difference was not significant in those with no previous doce
31 seconds (change of 56 seconds [95% CI, 14 to 98]), but this difference was not significant (mean difference in change in
33 y to receive chemotherapy than non-Hispanic whites, but the difference was not significant (OR, 0.83; 95% CI, 0.64 to 1.0
34 .9%, 83.3%, 95.9%, 80.0%, and 92.6%, respectively), but the difference was not significant (P > 0.05).
35 % CI: 81.0%, 92.0%) was higher than that for session 2, the difference was not significant (P = .08).
36 more discrepancies after more consecutive days worked, the difference was not significant (P = .0893).
37 %] vs 44 of 112 [39.3%], respectively), although the latter difference was not significant (P = .09).
38 nosed slightly earlier compared with atypical ARS, but this difference was not significant (P = .3).
39 r FFMI accretion than having 0% milk protein, although this difference was not significant (p = 0.055), and there was no
40 was slightly smaller on static images (-2% +/- 7%), but the difference was not significant (P = 0.14).
41 as 64.5% in group A and 70.2% in group B at study end, this difference was not significant (P = 0.28; hazard ratio [HR],
42 d approximately 30% greater survival than controls, but the difference was not significant (P= .14).
43 te-induced DA release tended to be lower in smokers but the difference was not significant (p=0.08).
44 (0.5 to 2.5) increase for women allocated placebo, but the difference was not significant (p=0.12).
45 and -253 pmol/L (-383 to -123) for the placebo group; this difference was not significant (p=0.77).
48 fit, but the point estimate was closer to no effect and the difference was not significant (RR 0.93, 95% CI 0.60-1.44).
49 e 1 cm group compared with the 3 cm group (253 vs 241), the difference was not significant (unadjusted HR 1.14 [95% CI 0.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。